オンコロジーベースのIn-Vivo CRO市場：サービス、適応症、エンドユーザー別-2025-2030年の世界予測

オンコロジーベースのIn-Vivo CRO市場は、2023年に12億7,000万米ドルと評価され、2024年には14億1,000万米ドルに達すると予測され、CAGR 11.34％で成長し、2030年には27億米ドルに達すると予測されています。

腫瘍学を基盤とする生体内CRO（医薬品開発業務受託機関）は、生体内における新規がん治療の包括的評価に重点を置き、前臨床試験のための幅広いサービスを提供します。正確には、これらのCROは、がん治療薬の有効性、安全性、薬物動態を評価する試験を実施し、医薬品開発の重要なステップを促進します。その必要性は、個別化医療への需要の高まりと、効果的ながん治療の絶え間ない追求に起因します。用途は創薬、トランスレーショナル・リサーチ、規制当局への申請など多岐にわたり、製薬会社、研究機関、バイオテクノロジー企業などの最終用途に供されています。この市場を牽引する主な成長要因としては、世界のがん罹患率の上昇、腫瘍学研究への投資の増加、動物モデリングにおける技術的進歩などが挙げられます。

臨床結果の予測モデリングを強化し、医薬品開発プロセスを合理化する人工知能とビッグデータ解析の統合により、最新のビジネスチャンスが生まれつつあります。革新的で費用対効果の高い試験デザインに向けた学界や新興バイオテクノロジー企業との提携も有望な手段です。しかし、この市場は、厳しい規制要件や動物実験に関する倫理的懸念といった課題に直面しており、これが試験プロセスを遅らせたり複雑化させたりしています。さらに、in-vitroモデルとの競合や、コスト制約による利害関係者の消極的な姿勢が大きな障壁となっています。

市場開拓は、より予測的で人道的な生体内モデルの開発、デジタルバイオマーカーの導入、動物実験から収集されるデータの精度向上に重点を置くことができます。企業は、結果の再現性を向上させ、離脱率を低下させる技術への投資を検討すべきです。この市場の性質はダイナミックであり、新たな科学的進歩や規制変更への適応性が重視されます。成長を目指す企業は、戦略的パートナーシップの形成、個別化試験モデルへの投資、進化する世界スタンダードへの準拠を優先し、急速に進化するこの分野で競争優位性を確保すべきです。

市場力学：急速に進化するオンコロジーベースのIn-Vivo CRO市場の主要市場インサイトを公開

オンコロジーベースのIn-Vivo CRO市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん罹患率の増加と効果的な創薬の必要性
  • 最適化された効率的ながん臨床試験活動のニーズの高まり
  • 個別化医療を奨励する政府の取り組み
• 市場抑制要因
  • データのセキュリティとプライバシーに関する懸念
• 市場機会
  • データ解析とAIによる腫瘍学ベースの生体内技術の進歩
  • バイオマーカー開発のためのオンコロジーCROサービスの拡大
• 市場の課題
  • がん臨床試験の規制遵守の限界

ポーターの5つの力：オンコロジーベースのIn-Vivo CRO市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：オンコロジーベースのIn-Vivo CRO市場における外部からの影響の把握

外部マクロ環境要因は、オンコロジーベースのIn-Vivo CRO市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析オンコロジーベースのIn-Vivo CRO市場における競合情勢の把握

オンコロジーベースのIn-Vivo CRO市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスオンコロジーベースのIn-Vivo CRO市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、オンコロジーベースのIn-Vivo CRO市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨オンコロジーベースのIn-Vivo CRO市場における成功への道筋を描く

オンコロジーベースのIn-Vivo CRO市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんの発生率増加と効果的な新薬発見の必要性
    • 最適化され効率的な腫瘍学臨床試験活動に対するニーズの高まり
    • 個別化医療を奨励する政府の取り組み
  • 抑制要因
    • データのセキュリティとプライバシーに関する懸念
  • 機会
    • データ分析とAIを活用した腫瘍学ベースの生体内技術の進歩
    • バイオマーカー開発のための腫瘍学CROサービスの拡大
  • 課題
    • 腫瘍学試験の規制遵守の限界
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 オンコロジーベースのIn-Vivo CRO市場：サービス別

• バイオマーカー開発
• 臨床試験管理
• 薬物動態研究
• 前臨床研究

第7章 オンコロジーベースのIn-Vivo CRO市場適応症別

• 造血悪性腫瘍
• 希少がん
• 固形腫瘍

第8章 オンコロジーベースのIn-Vivo CRO市場：エンドユーザー別

• 学術調査機関
• バイオテクノロジー企業
• 製薬会社

第9章 南北アメリカのオンコロジーベースのIn-Vivo CRO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のオンコロジーベースのIn-Vivo CRO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのオンコロジーベースのIn-Vivo CRO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Altogen Labs
• Cellvax, SAS
• Charles River Laboratory
• Crown Bioscience
• Cyagen Biosciences
• Evotec SE
• Explicyte by Immusmol SAS Company
• Icon PLC
• Imavita
• IVRS AB
• Laboratory Corporation of America Holdings
• Melior Discovery
• Noble Life Sciences
• Pharmaron
• Pharmatest Services
• Reaction Biology by Copeba
• Redoxis AB
• Taconic Biosciences, Inc.
• The Jackson Laboratory
• XenTech

LIST OF FIGURES

• FIGURE 1. ONCOLOGY BASED IN-VIVO CRO MARKET RESEARCH PROCESS
• FIGURE 2. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ONCOLOGY BASED IN-VIVO CRO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ONCOLOGY BASED IN-VIVO CRO MARKET DYNAMICS
• TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACOKINETICS STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RARE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023

The Oncology Based In-Vivo CRO Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.41 billion in 2024, and is projected to grow at a CAGR of 11.34%, to USD 2.70 billion by 2030.

The scope of oncology-based in-vivo CROs (Contract Research Organizations) involves providing a wide range of services for preclinical studies, focusing on the comprehensive assessment of novel cancer therapies in living organisms. Precisely, these CROs conduct studies that evaluate the efficacy, safety, and pharmacokinetics of oncology drugs, facilitating a critical step in drug development. Their necessity stems from the increasing demand for personalized medicine and the relentless pursuit of effective cancer treatments. Applications are versatile, including drug discovery, translational research, and regulatory submissions, serving end-uses in pharmaceutical companies, research institutions, and biotech firms. Key growth factors driving this market include the rising incidence of cancer worldwide, growing investments in oncology research, and technological advancements in animal modeling.

Latest opportunities are emerging with the integration of artificial intelligence and big data analytics, which enhance the predictive modeling of clinical outcomes and streamline drug development processes. Leveraging collaborations with academia and emerging biotech for innovative, cost-effective study designs is also a promising avenue. However, the market faces challenges such as stringent regulatory requirements and ethical concerns related to animal testing, which can delay and complicate study processes. Additionally, competition from in-vitro models and reluctance from stakeholders due to cost constraints are substantial barriers.

Market innovations could focus on developing more predictive and humane in-vivo models, incorporating digital biomarkers, and enhancing the precision of data gathered from animal studies. Companies should consider investing in technologies that improve the reproducibility of results and reduce attrition rates. The nature of this market is dynamic, with a strong emphasis on the adaptability to new scientific advancements and regulatory changes. Businesses aiming for growth should prioritize forming strategic partnerships, investing in personalized study models, and ensuring compliance with evolving global standards to secure a competitive advantage in this rapidly evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Based In-Vivo CRO Market

The Oncology Based In-Vivo CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of cancer and need for effective drug discovery
  • Rising need for optimized and efficient oncology clinical trial activities
  • Government initiatives encouraging personalized medicine
• Market Restraints
  • Concerns associated with data security and privacy
• Market Opportunities
  • Advancements in oncology-based in-vivo technologies with data analytics and AI
  • Expansion of oncology CRO services for biomarker development
• Market Challenges
  • Limitations of regulatory compliance of oncology trials

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Based In-Vivo CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Based In-Vivo CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Based In-Vivo CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Based In-Vivo CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Based In-Vivo CRO Market

A detailed market share analysis in the Oncology Based In-Vivo CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Based In-Vivo CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Based In-Vivo CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Based In-Vivo CRO Market

A strategic analysis of the Oncology Based In-Vivo CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Based In-Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Altogen Labs, Cellvax, SAS, Charles River Laboratory, Crown Bioscience, Cyagen Biosciences, Evotec SE, Explicyte by Immusmol SAS Company, Icon PLC, Imavita, IVRS AB, Laboratory Corporation of America Holdings, Melior Discovery, Noble Life Sciences, Pharmaron, Pharmatest Services, Reaction Biology by Copeba, Redoxis AB, Taconic Biosciences, Inc., The Jackson Laboratory, and XenTech.

Market Segmentation & Coverage

This research report categorizes the Oncology Based In-Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Services, market is studied across Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies, and Preclinical Studies.
• Based on Indication, market is studied across Hematological Malignancies, Rare Cancer, and Solid Tumor.
• Based on End-User, market is studied across Academic & Research Institutes, Biotechnology Companies, and Pharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of cancer and need for effective drug discovery
    • 5.1.1.2. Rising need for optimized and efficient oncology clinical trial activities
    • 5.1.1.3. Government initiatives encouraging personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with data security and privacy
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in oncology-based in-vivo technologies with data analytics and AI
    • 5.1.3.2. Expansion of oncology CRO services for biomarker development
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations of regulatory compliance of oncology trials
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncology Based In-Vivo CRO Market, by Services

• 6.1. Introduction
• 6.2. Biomarker Development
• 6.3. Clinical Trial Management
• 6.4. Pharmacokinetics Studies
• 6.5. Preclinical Studies

7. Oncology Based In-Vivo CRO Market, by Indication

• 7.1. Introduction
• 7.2. Hematological Malignancies
• 7.3. Rare Cancer
• 7.4. Solid Tumor

8. Oncology Based In-Vivo CRO Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Biotechnology Companies
• 8.4. Pharmaceutical Companies

9. Americas Oncology Based In-Vivo CRO Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Oncology Based In-Vivo CRO Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Based In-Vivo CRO Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Altogen Labs
• 2. Cellvax, SAS
• 3. Charles River Laboratory
• 4. Crown Bioscience
• 5. Cyagen Biosciences
• 6. Evotec SE
• 7. Explicyte by Immusmol SAS Company
• 8. Icon PLC
• 9. Imavita
• 10. IVRS AB
• 11. Laboratory Corporation of America Holdings
• 12. Melior Discovery
• 13. Noble Life Sciences
• 14. Pharmaron
• 15. Pharmatest Services
• 16. Reaction Biology by Copeba
• 17. Redoxis AB
• 18. Taconic Biosciences, Inc.
• 19. The Jackson Laboratory
• 20. XenTech